Lb Pharmaceuticals (LBRX) Capital Expenditures (2024 - 2026)

Lb Pharmaceuticals' Capital Expenditures history runs 3 years deep, the most recent figure standing at $32000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures rose 52.38% year-over-year to $32000.0; the TTM figure through Mar 2026 stood at $331000.0 (changed N/A YoY), while the FY2025 annual figure was $52000.0, down 93.24% from the prior year.
• Capital Expenditures for Q1 2026 stood at $32000.0, down from $40000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $238000.0 in Q4 2024, with the low at $21000.0 in Q1 2025.
• The 3-year median for Capital Expenditures is $36000.0 (2025), against an average of $82750.0.
• The sharpest annual moves came in 2025 and 2026: Capital Expenditures tumbled 83.19% in 2025, then soared 52.38% in 2026.
• Lb Pharmaceuticals' Capital Expenditures stood at $238000.0 in 2024, then slumped by 83.19% to $40000.0 in 2025, then slipped by 20.0% to $32000.0 in 2026.
• Business Quant data shows LBRX's Capital Expenditures at $32000.0 in Q1 2026, $40000.0 in Q4 2025, and $21000.0 in Q1 2025.